| |  Online-Ressource |
|---|
| Verfasst von: | Kriegsmann, Katharina [VerfasserIn]  |
|---|
| | Cremer, Martin [VerfasserIn] |
|---|
| | Harms, Alexander [VerfasserIn] |
|---|
| | Winter, Hauke [VerfasserIn] |
|---|
| | Kazdal, Daniel [VerfasserIn] |
|---|
| | Kriegsmann, Mark [VerfasserIn] |
|---|
| Titel: | Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer |
|---|
| Verf.angabe: | Katharina Kriegsmann, Martin Cremer, Christiane Zgorzelski, Alexander Harms, Thomas Muley, Hauke Winter, Daniel Kazdal, Arne Warth, Mark Kriegsmann |
|---|
| E-Jahr: | 2019 |
|---|
| Jahr: | 21 February 2019 |
|---|
| Umfang: | 6 S. |
|---|
| Fussnoten: | Gesehen am 26.04.2019 |
|---|
| Titel Quelle: | Enthalten in: Pathology |
|---|
| Ort Quelle: | Amsterdam : Elsevier, 1969 |
|---|
| Jahr Quelle: | 2019 |
|---|
| Band/Heft Quelle: | 51(2019), 3, Seite 240-245 |
|---|
| ISSN Quelle: | 1465-3931 |
|---|
| Abstract: | Summary - Histological subtyping of non-small cell lung cancer (NSCLC) is of utmost importance for therapy stratification. Common immunohistochemical markers to identify squamous lineage are CK5/6, p40, and p63. Although p40 is considered the gold standard by current guidelines, the agreement of all three markers is an important aspect for tumours more difficult to classify. A total of 1244 NSCLC including 569 squamous cell carcinomas (SqCC) and 675 adenocarcinomas were assembled on a tissue microarray and stained with CK5/6, p40, p63, TTF-1, and Napsin-A. Sensitivity and specificity for squamous lineage markers as well as agreement of CK5/6, p40 and p63 were calculated. Sensitivity of CK5/6, p40, and p63 for SqCC was 93%, 94%, and 94% and specificity was 98%, 97%, and 84%, respectively. Positivity for two of these markers was found in at least in 90% of SqCC. Highest agreement was observed for p40 and p63 (Cohen's kappa 0.80). We report a similar sensitivity of CK5/6, p40, and p63, but a decreased specificity of p63 as compared to CK5/6 and p40 for the identification of squamous lineage. Our results support the use of either CK5/6 or p40 over p63 in the routine diagnostic setting. |
|---|
| DOI: | doi:10.1016/j.pathol.2018.11.009 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1016/j.pathol.2018.11.009 |
|---|
| | Volltext: http://www.sciencedirect.com/science/article/pii/S0031302518304902 |
|---|
| | DOI: https://doi.org/10.1016/j.pathol.2018.11.009 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | CK5/6 |
|---|
| | lung cancer |
|---|
| | NSCLC |
|---|
| | p40 |
|---|
| | p63 |
|---|
| K10plus-PPN: | 1663669120 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer / Kriegsmann, Katharina [VerfasserIn]; 21 February 2019 (Online-Ressource)
